Loading data for ATRC — first visit, this takes a few seconds.

Alerta

AtriCure Inc. (ATRC)

NasdaqGM: ATRC · Precio en tiempo real · USD

47.62

+1.86 (4.06%)

Al cierre: Aug 19, 2026, 2:04 PM

4.06% (1D)

No hay datos disponibles

Precio de compra	27.83
Capitalización de mercado	2.42B
Ingresos (TTM)	569.62M
Beneficio neto (TTM)	10.55M
Beta	1.23
EPS (TTM)	0.21
Ratio PER (TTM)	226.74
Adelante PE	110.28
P/B (TTM)	4.69
P/S (TTM)	4.25
Earnings Date	May 5, 2026

Precio de venta	49.7
Volumen	62,605
Volumen medio (20D)	910,843
Abierto	46.28
Anterior Cerrar	45.76
Rango del día	46.28 - 47.67
Rango de 52 semanas	25.36 - 47.67
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de ATRC

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a ...

[Leer más]

Industria Medical Instruments & Supplies

Sector Healthcare

IPO Fecha Aug 5, 2005

Empleados 1,350

Bolsa de Valores NasdaqGM

Símbolo bursátil ATRC

Sitio web https://www.atricure.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de AtriCure fueron 534.53M, un aumento de 14.88% en comparación con 465.31M del año anterior. Las ganancias fueron -11.45M, una disminución de -74.39%.

Estados financieros

Sorpresa de resultados

AtriCure ha publicado sus resultados trimestrales en Jul 23, 2026:

Ingresos de $153.6M falla las estimaciones por $0, con 12.83% Crecimiento interanual.

EPS de 0.18 supera las estimaciones en 0.16, con 228.57% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que AtriCure Inc. publique sus resultados el May 5, 2026, después del cierre del mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 semana hace · MarketBeat

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

AtriCure (NASDAQ:ATRC) said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoptio...

1 semana hace · Motley Fool

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

The sale came at $38.42 per share, slightly below the day's market close, as AtriCure maintains its $2.0 billion market cap in the medical device sector.

1 semana hace · Motley Fool

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Prange's open-market disposition reduced her direct holdings by 14%, though she retains over 22,800 shares in the $2.0 billion medical device company.

2 semanas hace · Simply Wall St.

Project Horizon and Outlook Upgrade Might Change The Case For Investing In Inspire Medical Systems (INSP)

Inspire Medical Systems recently appointed AtriCure CEO Michael H. Carrel to its Board and committees, while long-serving director Casey M. Tansey plans to retire, as the company reported quarterly re...

2 semanas hace · Zacks

Are Options Traders Betting on a Big Move in AtriCure Stock?

Investors need to pay close attention to ATRC stock based on the movements in the options market lately.

Página 1 de 2

AtriCure Inc. (ATRC)